HIV/AIDS

The pandemic had an immediate effect on patient care, and in pivoting to adapt to the quarantine, some changes may have created potentially permanent ways to deliver health care.

In this 9-part series, we explore how the COVID-19 pandemic may permanently change health care, treatment, and research in the future.

Cabotegravir’s FDA breakthrough designation along with adaptive strategies being deployed are the biggest stories in HIV prevention this year.

Living longer because of antiretroviral therapy (ART), people with HIV (PWH) need to be counseled for age-related medical issues, and may also be eligible for newer ART. However, social determinants, stigma about the virus, and continuum of care issues remain challenges to many within the PWH population.

Our annual series is touching on the stories in medicine that occurred during this unforgettable time.

HIV care may help enable better treatment for HCV infectious.

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

A famed virologist weighs in on the country's earliest shortcomings—and how they can still be resolved today.

A majority of those who fall under the criteria for recommended HIV testing has not once received such testing.

The ID-Cap System represents the only ingestible event marker able to transmit digital data within the body to an external receiver without direct skin contact.

The FDA approves Descovy to reduce the risk of HIV infection through sex.

HIV patients will be allowed to switch to doravirine or doravirine/lamivudine/tenofovir disoproxil fumarate if they are virally suppressed with no prior history of treatment failure.

A study from the University of California San Francisco found that patients with HIV were at an 80% increased risk of suffering from atrial fibrillation.

A randomized trial compared cash incentives, peer support, and usual care for increasing rate of HCV treatment among HCV/HIV infected people who use drugs.

People experiencing homelessness were more likely to follow-up on referrals from an ophthalmology clinic if they had finished high school or had a primary care provider.

Steatosis was found more often with HCV monoinfection than with HCV/HIV and more commonly detected with imaging than with biopsy.

After initiating treatment with Symtuza within 2 weeks of HIV diagnosis, 84% of patients achieved undetectable viral loads at 48 weeks.

Dovato is a 2-drug regimen approved for treatment-naïve adult patients with HIV infection.

Sustained virologic response rates were high among HCV/HIV coinfected patients with early treatment discontinuation the only factor associated with lower SVR rate.

A new study confirmed that HIV infection significantly increases the risk of death for patients with hepatocellular carcinoma.

A new study finds patients who have high, real, or perceived risk of HIV are more likely to accept PrEP when they have access to it.

The FDA will decide this year whether the once-daily Merck therapies can be marketed as a switch-on drug for patients with suppressed HIV-1.

A new review shows transgender women face higher HIV rates than transgender men, but also finds a relative lack of data about transmen.

New research finds participants don’t always accurately report—or know—their HIV status when enrolling in studies.

Canadian investigators identified the role of media in both promulgating and mitigating stigma of PrEP for preventing HIV transmission.

New research finds patients face a higher risk of pneumonia if they are taking opioids. The danger is even more pronounced for patients living with HIV.

A new analysis finds racial and ethnic disparities vary significantly from state to state when it comes to sexually transmitted infection rates among men who have sex with men.

In theory, the combination of ART and PrEP would be enough to virtually eradicate HIV. In the real world, they’re falling well short.

MD Magazine's most popular stories this year ranged from new clinical insights, to physician-submitted columns, to perspectives on burnout in the workplace.

The CDC found that "provider-advised deferral" of HIV antiretroviral therapy occurring less, but that US still far from goal of universal prescribing.